Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 9102 results

  1. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  2. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  3. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  4. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  5. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628

    In development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 July 2026.

    Technology appraisal guidance
    In consultation

  8. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  9. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  10. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  11. Polyendocrine Metabolic Ovarian Syndrome (PMOS): draft guidance

    We are listening to your views on this NICE guideline. Comments close 11 August 2026.

    NICE guideline
    In consultation

  12. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]

    Deferred Reference number: GID-TA10905

    Technology appraisal guidance
    Deferred

  13. Polyendocrine Metabolic Ovarian Syndrome (PMOS)

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development

  14. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    Awaiting development Reference number: GID-TA12518 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development